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Biomarkers, Genomics, Proteomics, and Gene Regulation
Is Expression or Activation of Src Kinase Associated
with Cancer-Specific Survival in ER-, PR- and HER2-
Negative Breast Cancer Patients?
Beatrix Elsberger,* Bingchao A. Tan,*
Thomas J. Mitchell,* Sylvia B.F. Brown,*
Elizabeth A. Mallon,† Sian M. Tovey,*
Timothy G. Cooke,* Valerie G. Brunton,‡
and Joanne Edwards*
From the Section of Surgery,* Division of Cancer Sciences and
Molecular Pathology, Faculty of Medicine, Glasgow Royal
Infirmary, Glasgow; the Department of Pathology,† Glasgow
Western Infirmary, Glasgow; and the Edinburgh Cancer
Research Centre,‡ University of Edinburgh, Edinburgh, United
Kingdom
The aim of the current study was to assess the expres-
sion levels of c-Src and phosphorylated Src kinase in
human breast cancers and to establish if these are
linked to oestrogen receptor, progesterone receptor,
and human epidermal growth factor receptor 2 status
or patient survival. Tissue microarray technology was
used to analyze 314 breast cancer specimens. Immu-
nohistochemistry was performed using antibodies to
c-Src, Y419Src, and Y215Src, and expression was as-
sessed using the weighted histoscore method. High
cytoplasmic c-Src kinase and high membrane phos-
phorylated activated Y419Src kinase was associated
with decreased disease-specific survival. In contrast,
phosphorylated activated nuclear and cytoplasmic
Y215Src kinase expression levels were significantly
associated with improved disease-specific survival.
When the cohort was subdivided according to ER/PR/
HER2 status, the ER-negative subgroup (105 patients) was
associated with improved disease-specific survival and
was found tobe independent bymultivariate analysiswith
a hazard ratio of 0.4 (interquartile range 0.2–0.8). High
cytoplasmic c-Src expression was associated with de-
creased survival; high expression of activated c-Src (Y215)
was associated with improved survival. This was poten-
tiated in the ER/HER2-negative subgroup. Hence, ad-
ministration of Src kinase inhibitors aiming to decrease
phosphorylation should be approached with caution,
especially in ER-negative patients. It is therefore essen-
tial to appropriately identify with the correct biomark-
ers which patients are most likely to respond to Src
inhibitors. (Am J Pathol 2009, 175:1389–1397; DOI:
10.2353/ajpath.2009.090273)
The nonreceptor tyrosine kinase, c-Src, is implicated as a
regulator of cell proliferation and survival and has a com-
plex role in cell adhesion, proliferation, and motility.1 In vitro
work has implicated c-Src in the development and progres-
sion of human breast carcinoma.2,3 However, there is little
evidence to support this observation in clinical specimens.
c-Src is composed of a C-terminal tail, kinase domain,
two protein-protein interaction domains (SH2, SH3) and a
unique amino-terminal domain that varies between Src fam-
ily members. c-Src is activated by a number of pathways.
First, dephosphorylation of Y530 by a number of phospha-
tases has been linked to activation. Second, the binding of
the SH2 and SH3 domains to various proteins (epidermal
growth factor receptor, human epidermal growth factor re-
ceptor 2 (HER2), fibroblast growth factor receptor, focal
adhesion kinase (FAK), p130CAS (4–6)) is thought to be
important in c-Src regulation. This direct association can
result in activation of the intrinsic tyrosine kinase activity of
Src and/or localization of Src to sites of action. For example,
platelet-derived growth factor or HER2-driven phosphoryla-
tion of c-Src at Y215 (SH2 domain) has been shown to block
binding along with the C-terminal regulatory sequence re-
sulting in a 50-fold activation of Src.7
Investigating the role of the Src kinase in breast cancer at
each activated phosphorylation site (Y215, Y419) along with
the total expression levels of the protein is required to de-
termine its significance. The site of Src expression within the
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cell should also be assessed. Classically, the association of
c-Src with the membrane is considered essential for
cellular transformation;8 however, the location of activated
Src protein in breast cancer is unclear in the litera-
ture2,9,10 with only one report of membranous staining. It
has been suggested that cytosolic Src functions for pro-
tein trafficking, and there is early intriguing data suggest-
ing a role for nuclear Src as a cell cycle regulator.11
Although cell line studies strongly support the role of
c-Src in breast cancer progression, translational studies
investigating human breast tumor expression and corre-
lation with expression and activation to clinical parame-
ters are surprisingly limited.2,3 There are currently few
published studies with data on expression of Src kinase
in clinical breast cancer specimens.
The hypothesis of this study is that c-Src expression
and or phosphorylation status is linked with decreased
breast cancer-specific survival. The aim of this study was
therefore to assess the expression levels of c-Src and
activated Src (at two different phosphorylation sites) in
human breast cancers and determine any correlation
with patient outcome measures.
Materials and Methods
Patients
A total of 314 patients were recruited. All patients were
diagnosed with operable invasive breast carcinoma be-
tween 1980 and 1999 in the Greater Glasgow area. These
patients received standard adjuvant treatment according
to protocols at the time of diagnosis. We only included
patients in our analysis when all clinical data, ER, PR and
HER2 status and full Src kinase and activated Src kinase
expression data, were available. Ethics approval was
granted by the local ethics committee.
Tissue Microarray Construction
Tissue microarrays (TMAs) were already available for use
in the current study, 0.6 mm2 cores of breast cancer
tissue, identified by the pathologist, were removed from
representative areas of the tumor taken from breast can-
cer patients at time of surgical resection. All TMA blocks
were constructed in triplicate.
Immunohistochemistry
Staining for ER, PR, and HER2 had been previously per-
formed for the cohort.12 Fluorescent in situ hybridization was
performed on tumors that scored 2 by the HERCEPT test
(DakoCytomation, Glostrup, Denmark). Tumors were
deemed as HER2 positive if scored 3 by HERCEPT test or
if 2 by HERCEPT test and amplified by fluorescent in situ
hybridization using the Pathvision test (Vysis, USA). Src
kinase and activated Src kinase expression (Y419Src and
Y215Src) was investigated using antibodies for c-Src
(36D10; Cell Signaling Technology, MA), Y416Src (Cell Sig-
naling Technology, Beverly, MA), and Y216Src (Santa Cruz
Biotechnology, Santa Cruz, CA). In humans, the two acti-
vating phosphorylation sites that were investigated in the
current study are amino acids Y215 and Y419. Antibodies
used relate to the rabbit sequence and not the human
sequence. Tissue sections were dewaxed and rehydrated
through graded alcohol. All three antibodies were incu-
bated in a preheated antigen retrieval solution (citrate
buffer, pH 6.0; Vector Laboratories, Burlingame , CA). An-
tigen retrieval was performed by heating tissue sections
under pressure for 5 minutes in a microwave. Endogenous
peroxidase activity was blocked by incubation in 0.3% hy-
drogen peroxide (H2O2) (c-Src and Y416Src) and 3% H2O2
solution (Y216Src). To reduce nonspecific binding, the tis-
sue sections were then incubated with 1.5% normal horse
serum (c-Src) and 5% normal horse serum (Y416Src and
Y216Src) (Vector Laboratories) in antibody dilutent
(DakoCytomation) for 20 minutes at room temperature.
Slides were incubated with c-Src (1/200 dilution, 4.32 g/
ml) for 60 minutes at room temperature. The phosphory-
lated antibodies (Y419Src, dilution 1/2000, 0.02 g/ml; and
Y216Src, dilution 1/25, 8g/ml) were incubated overnight at
4°C. Signal was amplified and visualized using the DAKO
Envision Kit (DakoCytomation) and the chromagen 3,3-
diaminobenzidine (Vector Laboratories). Sections were
counterstained, dehydrated, and mounted. In each run, a
positive and negative isotype-matched control was in-
cluded to ensure no false-positive staining or intense
stromal staining. Specificity of all antibodies was con-
firmed by Western blotting.
Scoring
Protein expression of each core (three per tumor speci-
men) was assessed using the weighted histoscore
method (H score method,13). The weighted histoscore
grades staining intensity as negative (0), weak (1), mod-
erate (2), and strong (3), then multiplication of the per-
centage of tumor cells within each category. The histo-
score ranged from zero (minimum) to 300 (maximum).
Agreement between observers was excellent and mea-
sured in interclass correlation coefficient, respectively. All
interclass correlation coefficient scores were above 0.84.
Statistical Analysis
Disease-specific survival rates were generated using the
Kaplan-Meier method. The log-rank test was used to
compare significant differences between subgroups us-
ing univariate analysis. On the basis of the results of the
univariate analysis, a multivariate analysis was then per-
formed. The multivariate stepwise Cox-regression analysis
was performed to identify factors that were independently
associated with disease-specific death. A stepwise back-
ward procedure was used to derive a final model of the
variables that had a significant independent relationship
with survival. To remove a variable from the model the
corresponding P value had to be 0.05.
Interrelationships between clinical parameters and ER,
PR and HER2 status were calculated using the 2 test.
Because of the number of statistical comparisons, a
value of P  0.01 was considered to be significant. Data
are expressed as median and range. The statistical anal-
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yses were performed using a statistical software package
(version 15.0; SPSS, Chicago, IL).
Results
Clinicopathological Details
Our full cohort consisted of 314 breast cancer patients (209
ER positive/105 ER negative and 149 PR positive/163 PR
negative) (Table 1; bold typeface used to highlight signifi-
cant results). Median age was 58 years (interquartile range
51–56). Forty-six percent of the cancer specimens were
pathologically graded as grades 2 and 3, median size of the
invasive cancer was 20 mm (IQR 15–30 mm). Forty-eight
percent of the patients were axillary lymph node positive.
Mean patient follow-up was 7.1 years (minimum follow-up
was 2.1 years and the maximum follow-up was 20 years).
Sixteen patients were lost to follow-up. During this period,
Table 1. The Interrelationships between the Clinicopathological Characteristics of Patients with Breast Cancer
Total patient cohort: 314 2 P values
Variables Numbers
Tumour
type Grade Size
LN
status
ER
status
PR
status
HER
status
c-Src
nuc
c-Src
cyto
c-Src
memb
Y419Src
nuc
Y419Src
cyto
Y419Src
memb
Y215Src
nuc
Y215Src
cyto
Y215Src
memb
Age (50 yr/
50 yr)
78/236 0.910 0.728 0.261 0.950 0.260 0.947 0.173 0.527 0.369 0.705 0.622 0.391 0.287 0.332 0.649 0.861
Tumour type
(duct/lob/
tub/others)
298/10/3/3 0.007 0.964 0.680 0.012 0.453 0.512 0.904 0.717 0.761 0.753 0.293 0.416 0.015 0.515 0.424
Grade (G1/
G2/G3)
22/146/146 0.001 0.301 0.001 0.001 0.003 0.019 0.001 0.017 0.627 0.069 0.001 0.006 0.674 0.372
Size (mm)
(20, 20–
50, 50)
126/169/19 0.001 0.048 0.169 0.010 0.695 0.177 0.029 0.061 0.044 0.002 0.061 0.921 0.399
Lymph node
(positive/
negative)
152/162 0.555 0.812 0.016 0.937 0.329 0.607 0.127 0.211 0.392 0.504 0.828 0.217
ER status
(positive/
negative)
209/105 0.0010.001* 0.037 0.001* 0.001* 0.143 0.108 0.001* 0.001 0.902 0.972
PR status
(positive/
negative)
149/163 0.001 0.237 0.001 0.001 0.412 0.042 0.001 0.014 0.266 0.087
HER2 status
(positive/
negative)
51/263 0.031 0.001 0.001 0.053 0.001 0.001 0.161 0.001† 0.075
c-Src nuc
(positive/
negative)
139/175 0.001 0.001 0.058 0.268 0.376 0.902 0.297 0.048
c-Src cyto
(positive/
negative)
139/175 0.001 0.687 0.001 0.001 0.745 0.009* 0.682
c-Src memb
(positive/
negative)
135/179 0.370 0.001 0.001 0.147 0.001* 0.054
Y419Src nuc
(positive/
negative)
122/192 0.001 0.004 0.042 0.005* 0.120
Y419Src cyto
(positive/
negative)
138/174 0.001 0.294 0.001* 0.489
Y419Src
memb
(positive/
negative)
153/161 0.690 0.001* 0.141
Y215Src
nuclear
(positive/
negative)
154/160 0.001 0.063
Y215Src cyto
(positive/
negative)
158/156 0.022
Y215Src
memb
(positive/
negative)
14/299
Histology: duct, ductal carcinoma; lob, lobular carcinoma; tub, tubular carcinoma, others including mucinous, mucoid and micropapillary carcinoma;
Grade, Bloom and Richardson grade; c-Src, total Src kinase; Y419Src, Src kinase phosphorylated at tyrosine site 419; Y215Src, Src kinase phosphorylated at
tyrosine site Y215; c-Src nuc, c-Src nuclear expression; c-Src cyto, c-Src cytoplasmic expression; c-Src memb, c-Src membrane expression; Y419Src nuc,
Y419Src nuclear expression; Y419Src cyto, Y419Src cytoplasmic expression; Y419Src memb, Y419Src membrane expression; Y215Src nuc, Y215Src nuclear
expression; Y215Src cyto, Y215Src cytoplasmic expression; Y215Src memb, Y215Src membrane expression. *, Negatively correlated; †, cytoplasmic
Y215Src kinase expression independent on multivariate analysis (P  0.005, Table 3) as HER2 being displaced from the Cox regression model.
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78 patients died of their cancer, and an additional 33 pa-
tients died of intercurrent disease. Correlations between the
clinicopathological characteristics of this cohort are shown
in Table 1.
Src Kinase Expression Levels
c-Src kinase
Each cellular location was independently assessed for
c-Src kinase expression levels. Forty-five percent of tu-
mors exhibited nuclear expression, 60% cytoplasmic,
and 43% membrane (Figure 1, A–C). Tumors were sub-
divided into those with high (above the median) or low
(below or equal to the median) expression. 2 analysis
demonstrated that grade and HER2 status positively cor-
related with cytoplasmic c-Src expression (Table 1). ER
status correlates negatively with cytoplasmic and mem-
brane c-Src expression (Table 1). c-Src expression in the
membrane only correlates with HER2 status (Table 1).
Expression levels of c-Src at each cellular location posi-
tively correlated with each other (Table 1). On univariate
analysis, neither membrane nor nuclear c-Src expression
was associated with disease-specific survival. Whereas
high cytoplasmic c-Src kinase expression was signifi-
cantly associated with shorter disease-specific survival
(P 0.028) (Figure 2A), but was not independent in mul-
tivariate analysis (Table 2; bold typeface used to high-
light positive correlations). Those patients with high
cytoplasmic c-Src expression had a median survival of
12.6 years (IQR 10.8–14.5) compared with those with
low expression with median survival of 14.6 years (IQR
12.8–16.5).
Y419Src kinase
Activated phosphorylated Src kinase expression, at
the classical activation site Y419, was predominately ob-
served in the nucleus (92%) and cytoplasm (76%) and
Figure 1. Images of immunohistochemistry (IHC) for each antibody. A–C shows breast tissue stained with c-Src antibody (1:200; Cell Signaling Technology); A
demonstrates negative stroma and negative breast tumor staining; magnification,100; B illustrates weak cytoplasmic and negative stroma staining; magnification,
100; C displays negative and weak cytoplasmic staining as well as negative and weak nuclear staining; magnification, 60. D–F shows breast tissue stained with
Y416Src antibody (1:2000; Cell Signaling Technology); D reveals weak cytoplasmic and weak nuclear staining; magnification, 100; E demonstrates strong nuclear and
moderate membrane staining; magnification,40; F displays strongmembrane staining; magnification,60.G–I shows breast tissue stained with Y216Src antibody (1:25;
Santa Cruz Biotechnology); G illustrates negative staining of stroma and tumor tissue; magnification, 100; H reveals weak cytoplasmic, weak nuclear and moderate
membrane staining; magnification, 100; I demonstrates negative cytoplasmic, moderate nuclear and weak membrane staining; magnification, 400.
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48% of tumors also expressed Y419Src kinase in the
membrane (Figure 1, D–F). 2 analysis demonstrated that
cytoplasmic Y419Src expression positively correlated
with HER2 status (Table 1). Membrane Y419Src expres-
sion positively correlated with grade, size, and HER2
status and inversely correlated with ER status (Table 1).
Nuclear Y419Src expression did not correlate with any
known clinicopathological features. Expression levels of
Y419Src at each cellular location strongly positively cor-
related with each other (Table 1). Only high membrane
expression was associated with shorter disease-specific
survival (P 0.023) on univariate analysis (Figure 2B) but
was not independent in multivariate analysis (Table 2).
Patients with high membrane Y419Src expression had a
median survival of 12.8 years (IQR 11.1–14.6) compared
with those with low expression with median survival of
14.8 years (IQR 12.1–16.8).
Y215Src kinase
Phosphorylated activated Y215Src kinase expression
was predominately observed in the nucleus (74%) and
cytoplasm (68%) (Figure 1, G–I). No more than 5% of
tumors expressed Y215Src kinase in the membrane. On
2 analysis, nuclear Y215Src expression positively corre-
lated with grade and ER status (Table 1). The only cor-
relation observed with cytoplasmic Y215Src expression
and clinicopathological features was a positive correla-
tion with HER2 status (Table 1).
In contrast, to the observations made with total c-Src
(associated with poor prognosis), high nuclear and cyto-
plasmic Y215Src kinase expression was strongly associ-
ated with improved disease-specific survival (nuc Y215Src,
P  0.001 (Figure 2C); cyto Y215Src, P  0.001 (Figure
2D)) (Table 2). Although cytoplasmic Y215Src kinase ex-
pression and HER2 status correlated on 2 analysis (Table
1), only cytoplasmic Y215Src kinase expression was inde-
pendent on multivariate analysis (P  0.005) with a hazard
ratio 0.5 (IQR 0.30.8), as HER2 was displaced from the
Cox-regression model. Patients with high nuclear Y215Src
kinase expression had a median survival of 15.0 years (IQR
13.1–16.8) compared with those with low expression with a
median survival of 12.3 years (IQR 10.5–14.2). Patients with
high cytoplasmic Y215Src kinase expression had a median
survival of 14.9 years (IQR 13.1–16.7) compared with those
Figure 2. Kaplan-Meier Curves for Src kinase expressions in the full cohort (n  314). A: Kaplan Meier Survival Curve cytoplasmic c-Src (P  0.028). B:
Kaplan-Meier Survival Curve membranous Y419Src (P  0.023). C: Kaplan-Meier Survival Curve nuclear Y215Src (P  0.001). D: Kaplan-Meier Survival Curve
cytoplasmic Y215Src (P  0.001).
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with low expression with a median survival of 12.5 years
(IQR 10.6–14.4).
Relationship of Src Kinase Expression to
Disease-Specific Survival in Patients Stratified
by ER Status
Src kinase and activated Src kinase expression was then
stratified by ER status (105 ER-negative and 209 ER-
positive tumors). In patients with ER-negative tumors, no
significant associations with survival were made with
membrane, cytoplasmic, or nuclear c-Src expression.
However, cytoplasmic Y215Src kinase expression was
significantly associated with improved disease-specific
survival (P  0.003) (Figure 3A) and was, as in the full
cohort, independent on multivariate analysis (P  0.007)
with a hazard ratio of 0.4 (IQR 0.20.8). No association
was observed in the ER-positive cohort (P  0.051)
(Figure 3B). In contrast, it was nuclear Y215 Src kinase
expression that was significantly associated with improved
disease-specific survival (P  0.003) (Figure 3D) in the
patients with ER-positive tumor, and this was also indepen-
dent on multivariate analysis (P 0.009) with a hazard ratio
of 0.4 (IQR 0.20.8). No association was observed in the
ER-negative cohort (P  0.345) (Figure 3C).
When patients with ER/HER2-negative tumors were an-
alyzed (n  75), cytoplasmic Y215 Src kinase was yet
again strongly associated with improved disease-free
survival (P 0.007) (Figure 4), and this was independent
on multivariate analysis (P  0.040) with a hazard ratio
of 0.3 (IQR 0.1–0.9) (Table 3; bold typeface used to
highlight significant results). This observation held
when ER/PR/HER2-negative tumors were analyzed
(n  71) (univariate analysis P  0.015, multivariate
analysis P  0.021).
Discussion
This study suggests that Src kinase expression and
phosphorylation status may be used as prognostic mark-
ers in breast cancer. Increased cytoplasmic c-Src kinase
expression is significantly associated with decreased
disease-specific survival. To our knowledge, this is cur-
rently the largest study investigating the role of Src kinase
expression and phosphorylation status in a cohort of
clinical breast cancer specimens. Most of the existing in
vitro literature provides compelling evidence that c-Src
activation is associated with high tumor proliferation, in-
creased invasion, and increased migration in breast can-
cer cells.1,14 This has been supported by an in vivo study
where Src kinase expression in ductal carcinoma in situ
breast tumors correlated with HER2 positivity, high tumor
grade, comedo necrosis, and elevated epithelial prolifer-
ation.3 In addition, high c-Src levels were associated with
lower recurrence-free survival. The results obtained from
our study are in keeping with those cell line studies,
Table 2. Impact of Clinicopathological Factors and Protein Expression/Activation on Patient Survival
Total patient cohort: 314
patients
Univariate analysis Multivariate analysis
Numbers P value HR IQR P value HR IQR
Age (50 yr/50 yr) 78/236 0.351 1.2 0.7–2.2
Tumour type
(ductal/lobular/tubular/others)
298/10/3/3 0.714 0.6 0.2–1.4
Grade (G1/G2/G3) 22/146/146 0.014 1.8 12.–2.7
Size
(20 mm, 20–50 mm, 50 mm)
126/169/19 0.001 3.1 2.1–4.8 0.001 6.7 3.2–14.2
Lymph node (positive/negative) 152/162 0.001 2.1 1.3–3.3 0.013 1.9 1.1–3.1
ER status (positive/negative) 209/105 0.001 2.3 1.5–3.6 0.027 1.8 1.1–3.0
PR status (positive/negative) 149/163 0.006 1.9 1.2–3.0 0.04 1.7 1.0–2.7
HER2 status (positive/negative) 51/263 0.010 1.9 1.6–3.2
c-Src nuclear expression
(positive/negative)
139/175 0.328 1.2 0.7–2.0
c-Src cytoplasm expression
(positive/negative)
139/175 0.028 1.6 1.1–2.6
c-Src membrane expression
(positive/negative)
135/179 0.784 0.94 0.6–1.5
Y419Src nuclear expression
(positive/negative)
122/192 0.585 0.87 0.5–1.4
Y419Src cytoplasm expression
(positive/negative)
138/174 0.625 0.88 0.6–1.4
Y419Src membrane expression
(positive/negative)
153/161 0.023 1.7 1.1–2.7
Y215Src nuclear expression
(positive/negative)
154/160 0.001 0.43 0.2–0.7
Y215Src cytoplasm expression
(positive/negative)
158/156 0.001 0.45 0.3–0.7 0.005 0.5 0.3–0.8
Y215Src membrane expression
(positive/negative)
14/299 0.601 0.74 0.2–2.3
Table 2 shows an overview of the full patient cohort’s characteristics. Each clinical and pathological parameter was correlated to disease-specific
survival (P values). Grade, Bloom and Richardson grade. Histology: ductal, ductal carcinoma; lobular, lobular carcinoma; tubular, tubular carcinoma;
others including mucinous, mucoid, and micropapillary carcinoma c-Src, total Src kinase; Y419Src, Src kinase phosphorylated at tyrosine site 419;
Y215Src, Src kinase phosphorylated at tyrosine site Y215.
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demonstrating that c-Src is associated with more aggres-
sive growth and poor clinical outcome. Confirmed in
the current study, c-Src expression correlated with
decreased survival, increased tumor grade, and ER and
HER positivity. Although it is important to assess c-Src
protein levels, it is of equal importance to determine the
activation status of Src kinase. Ito et al.2 reported that
high activated c-Src expression was frequently observed
in breast tumors with lower aggressiveness as indicated
by low Ki-67, absence of lymph node spread, small size,
and a low histological grade. This suggests that activa-
tion of Src is associated with early stages of breast car-
cinoma, but there was no correlation made with patient
outcome measures.2 However, Src activation was deter-
mined using an antibody to tyrosine site 530 and was
classed as activated if unphosphorylated at this site. It
has previously been suggested that a more appropriate
biomarker for prediction of clinical response to Src kinase
inhibitors would to be to measure phosphorylation of the
protein at a site associated with activity.15,16 Currently,
there are two sites within c-Src known to be associated
with activation. Y419Src is known as the classical site,
which is most commonly used in cell line studies inves-
tigating the functional relevance of Src kinase activa-
tion.17 Src kinase when activated is moved to the mem-
Figure 3. Kaplan-Meier Survival Curves for Y215Src expression for ER positive (n 209) and negative (n 105) subgroups. A: Kaplan-Meier Survival Curve for nuclear
Y215Src in ER-negative patients (P 0.345). B: Kaplan-Meier Survival Curve for nuclear Y215Src in ER-positive patients (P 0.003). C: Kaplan-Meier Survival Curve for
cytoplasmic Y215Src in ER-negative patients (P  0.003). D: Kaplan-Meier Survival Curve for cytoplasmic Y215Src in ER-positive patients (P  0.051).
Figure 4. Kaplan-Meier Survival Curve for cytoplasmic Y215Src in ER/HER2-
negative patients (P  0.007).
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brane.1 Indeed, in the current study, when Src kinase is
activated at the classical site Y419 and located in the
cellular membrane, it is associated with shorter disease-
specific survival, increasing grade, tumor size, ER nega-
tivity, and HER2 positivity. Although our results with Y419
support the role of Src kinase activation, currently de-
scribed in the literature, we have contradictory results
with an alternative phosphorylation site Y215 (Figure 5, A
and B). Interestingly, the current study observes poor
prognosis associated with membrane expression of
phosphorylated Y419Src and good prognosis with cyto-
plasmic expression of phosphorylated Y215Src. These
results suggest that location and not only phosphoryla-
tion site influences downstream effectors of Src kinase.
Stover et al7 report a 50-fold increase in activation of
Src kinase associated with Y215Src phosphorylation.
In the current study, using clinical specimens, phos-
phorylation at this site is strongly associated with im-
proved survival (high nuclear and cytoplasmic
Y215Src expression) and was demonstrated to be in-
dependent of other known clinical parameters on mul-
tivariate analysis (only seen with high cytoplasmic
Y215 Src kinase expression). It is unclear why Y419Src
and Y215Src are associated with different outcome
measures. These contrasting roles may be due to
phosphorylation at Y215 and Y419 residing in different
SH domains. Phosphorylation in different domains may
result in varying protein configurations, which might
enable activation of other downstream signaling path-
ways. An alternative explanation of these results may
be that the antibodies detect phosphorylation of other
Src kinase family members (e.g., Lyn, Fck, Yes) in
addition or in preference to c-Src, because the phos-
phorylated regions are highly conserved.7
Table 3. Impact of Clinicopathological Factors and Protein Expression/Activation on Patient Survival in ER/HER2-Negative
Patients
ER/HER2-negative patients: 75 patients
Univariate
analysis Multivariate analysis
Numbers P value HR IQR P value HR IQR
Grade (G1/G2/G3) 1/13/61 0.214 2.0 0.9–4.5
Size (20 mm, 20–50 mm, 50 mm) 31/37/7 0.001 5.2 1.9–14.7 0.030 5.1 1.7–15.0
Lymph node (positive/negative) 35/40 0.021 2.4 1.1–5.4 0.005 3.3 1.4–7.5
c-Src nuclear expression (positive/negative) 39/36 0.747 1.1 0.5–2.4
c-Src cytoplasm expression (positive/negative) 39/36 0.412 1.4 0.6–3.0
c-Src membrane expression (positive/negative) 36/39 0.636 1.2 0.6–2.6
Y419Src nuclear expression (positive/negative) 17/58 0.340 1.6 0.6–4.3
Y419Src cytoplasm expression (positive/negative) 27/48 0.522 1.3 0.6–2.9
Y419Src membrane expression (positive/negative) 41/34 0.692 1.2 0.5–2.5
Y215Src nuclear expression (positive/negative) 22/53 0.590 1.3 0.5–3.0
Y215Src cytoplasm expression (positive/negative) 30/45 0.007 0.3 0.1–0.8 0.040 0.3 0.1–0.9
Y215Src membrane expression (positive/negative) 3/72 0.771 1.3 0.2–10.1
Table 3 shows an overview of the ER/PR/HER2-negative patients’ characteristics. Each clinical and pathological parameter was correlated to
disease specific survival (P values). Grade, Bloom and Richardson grade. Histology: ductal  ductal carcinoma; lobular, lobular carcinoma; tubular,
tubular carcinoma; others including mucinous, mucoid, and micropapillary carcinoma c-Src, total Src kinase; Y419Src, Src kinase phosphorylated at
tyrosine site 419; Y215Src, Src kinase phosphorylated at tyrosine site Y215.
Figure 5. Schematic representation of the interac-
tion between Src kinase, activated Src kinase, es-
trogen receptor, HER2, and prognosis; highlight-
ing that in the ER-negative cohort membranous
Y419Src kinase correlates positively with HER2
while cytoplasmic Y215Src kinase is associated
with good prognosis (colored in green) and cor-
relates negatively with HER2 (A). P values stated
within the ovals represent the association of Src
kinase expression with overall survival. Ovals col-
ored in blue were not significantly associated with
survival. In the full cohort, cytoplasmic Src kinase
and membranous activated Y419Src kinase is as-
sociated with poor prognosis (colored in red) and
correlates negatively with ER and positively with
HER2 status. As in the negative cohort cytoplasmic
activated Y215Src kinase is associated with good
prognosis, but correlates positively with HER2 sta-
tus (B).
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Activated phosphorylated Y215Src kinase was inde-
pendent in multivariate analysis (tumor grade, tumor size,
axillary lymph node involvement, ER, and HER2 status),
providing evidence that Y215Src could be used as a
prognostic marker to determine which subgroup of
breast cancer patients should not be targeted with Src
kinase inhibitors. Although Y215Src was independent on
multivariate analysis, there was a positive association
observed between cytoplasmic Y215Src kinase expres-
sion and HER2 status. These results support the obser-
vation that HER2 may phosphorylate Src kinase at
Y215.18 Vadlamudi et al18 suggested that the interaction
with HER2 would result in a more aggressive phenotype
of cancer. This is in direct contrast with results obtained
in the current study. Further investigations, to determine
the underlying molecular interactions between HER2 and
Src kinase, are therefore warranted.
Approximately 10 to 15% of breast cancers fall into the
receptor negative or triple negative group of breast can-
cers as defined by the absence of ER, PR, and HER2
receptors. This group of breast tumors are currently the
focus of much attention because of their poor prognosis
and the lack of an effective treatment target.19,20 In vitro
studies, using gene expression profiling, have identified
triple negative breast cancer tumors to be sensitive to
dasatinib, a nonreceptor tyrosine kinase inhibitor. A re-
duction in cell proliferation was demonstrated.17 When
we examined the ER-, PR-, and HER2-negative breast
tumors as a representation of the triple-negative group of
breast tumors, we found that high cytoplasmic Y215 Src
kinase expression resulted again in a significant survival
advantage. With Src inhibitors being trialed clinically, it
needs to be established which phosphorylation site they
target. If subsequent experimental data demonstrates
Src kinase inhibitors targeted Y215, these drugs could be
potentially harmful to this specific subgroup of patients.
Caution should be applied before these drugs are
administered.
In conclusion, high expression of cytoplasmic c-Src
kinase and membranous-activated Y419Src kinase are
associated with a reduction in disease-specific survival.
In contrast, activation of cytoplasmic Src kinase at Y215
is associated with improved disease-specific survival,
especially in ER-negative patients. Therefore, inhibition of
Src phosphorylation via Src inhibitors may possibly be
harmful to this particular subgroup. More detailed studies
must be conducted to support these findings, especially
in view of a large number of Src inhibitors entering clinical
trials.
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